Navigation Links
Sagent Pharmaceuticals Bolsters Antibiotics Offering With Two Product Launches

SCHAUMBURG, Ill., Dec. 1 /PRNewswire/ -- Sagent Pharmaceuticals, Inc., a privately held specialty pharmaceutical company, today announced the launch of two antibiotics: cefoxitin for injection, USP and ceftriaxone for injection, USP. Both are antibiotics of the cephalosporin family and have activity against gram-positive and gram-negative bacteria. Sagent will launch ceftriaxone in a 10 g vial in December to complement the four vial sizes launched by Sagent in July 2008. Cefoxitin 1 g and 2 g vials are now available. According to 2008 IMS data, the approximate U.S. market was $19 million for cefoxitin for injection and $113 million for the ceftriaxone for injection product line.

"We are pleased to add two presentations of cefoxitin, and the ceftriaxone line extension, which provides an important ceftriaxone pharmacy bulk package option for customers, to our portfolio of antibiotics," said Jeffrey M. Yordon, chief executive officer, founder, and chairman of the board of Sagent. "Even as our antibiotics portfolio, in particular, continues to grow, we remain focused on offering our customers a broad array of specialty injectables, all of which are latex free and feature our signature packaging enhancements."

About Cefoxitin for Injection, USP

Cefoxitin for injection, USP is indicated for the treatment of serious infections caused by susceptible strains of designated microorganisms in these diseases: lower respiratory tract infections, including pneumonia and lung abscess; urinary tract infections; intra-abdominal infections, including peritonitis and intra-abdominal abscess; gynecological infections, including endometritis, pelvic cellulitis, and pelvic inflammatory disease; septicemia; bone and joint infections; and skin and skin structure infections.

About Ceftriaxone for Injection, USP

Ceftriaxone for injection, USP is a broad spectrum cephalosporin antibiotic used to treat a variety of infections. Ceftriaxone for injection is indicated for infections of the lower respiratory tract, urinary tract, skin and skin-structure, intra-abdomen, and bones and joints, as well as acute otitis media, uncomplicated gonorrhea, pelvic inflammatory disease, bacterial septicemia and meningitis. Ceftriaxone may also reduce the incidence of postoperative infections is used as a surgical prophylaxis preoperatively.

Package inserts for cefoxitin for injection, USP and ceftriaxone for injection, USP are available at and contain detailed information about the indications, complete side effect profiles, and prescribing information.

About Sagent Pharmaceuticals, Inc.

Sagent Pharmaceuticals, founded in 2006, is a privately held specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products. Sagent has created a unique, global network of resources, comprised of rapid development capabilities, sophisticated manufacturing and innovative drug-delivery technologies, quickly yielding an extensive portfolio of pharmaceutical products that fulfills the evolving needs of patients. Sagent currently has more than 200 products in development.

To Discover Injectables Excellence(TM) and learn more about Sagent, please visit

SOURCE Sagent Pharmaceuticals, Inc.

SOURCE Sagent Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Sagent Pharmaceuticals Announces Launch of Adenosine Injection, USP, in 6 mg per 2 mL Single-Dose Vials
2. Sagent Pharmaceuticals Launches Vinorelbine Injection, USP
3. Sagent Pharmaceuticals to Present at Two Upcoming Financial Conferences
4. Sagent Pharmaceuticals to Present at Piper Jaffray Health Care Conference
5. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
8. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
9. ( Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
10. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
11. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
Post Your Comments:
(Date:11/26/2015)... , November 26, 2015 /PRNewswire/ ... announced the addition of the  "2016 ... the European Therapeutic Drug Monitoring (TDM) ... Competitive Intelligence, Emerging Opportunities"  report to ... ) has announced the addition of ...
(Date:11/26/2015)... ) has announced ... High Viscosity Drugs" report to their offering. ... addition of the "Self Administration of High ... --> Research and Markets ( ) ... Administration of High Viscosity Drugs" report to ...
(Date:11/26/2015)... , November 26, 2015 ... addition of the "Radioimmunoassay Market by ... (Hospital, Pharmaceutical Industry, Academics, Clinical Diagnostic Labs), ... Global Forecast to 2020" report to ... has announced the addition of the ...
Breaking Medicine Technology:
(Date:11/28/2015)... , ... November 28, 2015 , ... Trying to relax ... created the COUCH BUDDY. "I conceived of this design due to personal experience with ... couch users. It promotes relaxation and convenience, as well as increases support. It also ...
(Date:11/27/2015)... ... November 27, 2015 , ... According to an article published ... Association meeting in Washington D.C. revolved around the fact that proper dental care, both ... talk stressed the link between periodontal disease (more commonly referred to as gum disease) ...
(Date:11/27/2015)... Raleigh, NC (PRWEB) , ... November 27, 2015 , ... ... most effective ways to treat it. Surviving Mesothelioma has just posted the findings ... Researchers at University Hospital Zurich analyzed the cases of 136 mesothelioma patients who were ...
(Date:11/27/2015)... ... November 27, 2015 , ... The print ... USA Today in Atlanta, Dallas, New York, Minneapolis, South Florida, with a circulation ... is distributed nationally, through a vast social media strategy and across a network ...
(Date:11/27/2015)... ... November 27, 2015 , ... Intellitec ... Dynamics SL User Group (MSDSLUG). Recognized as Microsoft’s official group for end users ... Dynamics SL software users, partners, industry experts and representatives. Intellitec Solutions’ membership status ...
Breaking Medicine News(10 mins):